Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Cerebrospinal fluid complement system biomarkers in demyelinating disease.

Zelek WM, Fathalla D, Morgan A, Touchard S, Loveless S, Tallantyre E, Robertson NP, Morgan BP.

Mult Scler. 2019 Nov 8:1352458519887905. doi: 10.1177/1352458519887905. [Epub ahead of print]

PMID:
31701790
2.

Early MRI predictors of prognosis in multiple sclerosis.

Davda N, Tallantyre E, Robertson NP.

J Neurol. 2019 Dec;266(12):3171-3173. doi: 10.1007/s00415-019-09589-2. No abstract available.

3.

A Case of Treatment Resistance and Complications in a Patient with Stiff Person Syndrome and Cerebellar Ataxia.

Jones LA, Baber W, Wardle M, Robertson NP, Morris HR, Church A, Llewelyn JG, Peall KJ.

Tremor Other Hyperkinet Mov (N Y). 2019 Oct 1;9. doi: 10.7916/tohm.v0.677. eCollection 2019.

4.

Cautious Interpretation of Observational Data-Reply.

Harding KE, Tallantyre EC, Robertson NP.

JAMA Neurol. 2019 Oct 14. doi: 10.1001/jamaneurol.2019.3459. [Epub ahead of print] No abstract available.

PMID:
31609382
5.

Cluster headache: an overview of established and emerging treatments.

Al-Ansari A, Robertson NP.

J Neurol. 2019 Oct 10. doi: 10.1007/s00415-019-09548-x. [Epub ahead of print] No abstract available.

6.

Treatment of progressive multifocal leukoencephalopathy.

Castle D, Robertson NP.

J Neurol. 2019 Oct;266(10):2587-2589. doi: 10.1007/s00415-019-09501-y. No abstract available.

7.

Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Castle D, Robertson NP.

J Neurol. 2019 Sep;266(9):2338-2340. doi: 10.1007/s00415-019-09485-9. No abstract available.

8.

Neurotoxicity of novel cancer immunotherapies.

Willis MD, Robertson NP.

J Neurol. 2019 Aug;266(8):2087-2089. doi: 10.1007/s00415-019-09444-4. No abstract available.

9.

Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis.

Lipp I, Jones DK, Bells S, Sgarlata E, Foster C, Stickland R, Davidson AE, Tallantyre EC, Robertson NP, Wise RG, Tomassini V.

Hum Brain Mapp. 2019 Jul;40(10):2917-2932. doi: 10.1002/hbm.24568. Epub 2019 Mar 19.

10.

Autoimmune encephalitis: frequency and prognosis.

Al-Ansari A, Robertson NP.

J Neurol. 2019 May;266(5):1287-1289. doi: 10.1007/s00415-019-09273-5. No abstract available.

11.

Technology-assisted recovery of walking after spinal cord injury.

Willis MD, Robertson NP.

J Neurol. 2019 Apr;266(4):1046-1048. doi: 10.1007/s00415-019-09227-x. No abstract available.

12.

Imaging in the diagnosis of progressive supranuclear palsy.

Smith MD, Schwartz S, Robertson NP.

J Neurol. 2019 Feb;266(2):545-547. doi: 10.1007/s00415-018-9148-5. No abstract available.

13.

Rituximab in neurological disease: principles, evidence and practice.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A.

Pract Neurol. 2019 Feb;19(1):5-20. doi: 10.1136/practneurol-2018-001899. Epub 2018 Nov 29. Review.

PMID:
30498056
14.

New rare genetic variants in multiple sclerosis.

Harding KE, Robertson NP.

J Neurol. 2019 Jan;266(1):278-280. doi: 10.1007/s00415-018-9128-9. No abstract available.

15.

Sarcoidosis following alemtuzumab treatment for multiple sclerosis.

Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, Coles A, Robertson NP.

Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11.

PMID:
30307364
16.

Secondary antibody deficiency in neurology.

Tallantyre EC, Robertson NP, Jolles S.

Curr Opin Allergy Clin Immunol. 2018 Dec;18(6):481-488. doi: 10.1097/ACI.0000000000000485. Review.

PMID:
30299398
17.

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Lilford R, Dobson C.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. doi: 10.1136/jnnp-2018-318360. Epub 2018 Sep 21.

18.

Anti-epileptics and pregnancy: an update.

Al-Ansari A, Robertson NP.

J Neurol. 2018 Nov;265(11):2749-2751. doi: 10.1007/s00415-018-9058-6. Review. No abstract available.

19.

How common is truly benign MS in a UK population?

Tallantyre EC, Major PC, Atherton MJ, Davies WA, Joseph F, Tomassini V, Pickersgill TP, Harding KE, Willis MD, Winter M, Robertson NP.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):522-528. doi: 10.1136/jnnp-2018-318802. Epub 2018 Sep 3.

20.

Correction to: Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease.

Willis MD, Robertson NP.

J Neurol. 2018 Oct;265(10):2469. doi: 10.1007/s00415-018-9019-0.

21.

New treatments in Alzheimer's disease.

Pickrell WO, Robertson NP.

J Neurol. 2018 Sep;265(9):2162-2163. doi: 10.1007/s00415-018-9018-1. No abstract available.

22.

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease.

Willis MD, Robertson NP.

J Neurol. 2018 Aug;265(8):1950-1952. doi: 10.1007/s00415-018-8963-z. No abstract available. Erratum in: J Neurol. 2018 Oct;265(10):2469.

23.

Transmissible amyloid protein: evidence from iatrogenic CJD.

Hu M, Robertson NP.

J Neurol. 2018 Jul;265(7):1726-1729. doi: 10.1007/s00415-018-8927-3. No abstract available.

24.

Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.

Beesley R, Anderson V, Harding KE, Joseph F, Tomassini V, Pickersgill TP, Robertson NP, Tallantyre EC.

Mult Scler. 2018 Nov;24(13):1786-1787. doi: 10.1177/1352458518778007. Epub 2018 May 15. No abstract available.

PMID:
29762077
25.

Monoclonal antibodies for migraine: an update.

Castle D, Robertson NP.

J Neurol. 2018 Jun;265(6):1491-1492. doi: 10.1007/s00415-018-8886-8. No abstract available.

26.

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.

Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinescu C, Robertson NP, Jacob A.

J Neurol. 2018 May;265(5):1123. doi: 10.1007/s00415-018-8833-8.

27.

Stem cells in the treatment of central nervous system disease.

McLauchlan D, Robertson NP.

J Neurol. 2018 Apr;265(4):984-986. doi: 10.1007/s00415-018-8818-7. No abstract available.

28.

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.

Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, Jacob A.

J Neurol. 2018 May;265(5):1115-1122. doi: 10.1007/s00415-018-8812-0. Epub 2018 Mar 6. Erratum in: J Neurol. 2018 Apr 7;:.

29.

Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.

Zelek WM, Watkins LM, Howell OW, Evans R, Loveless S, Robertson NP, Beenes M, Willems L, Brandwijk R, Morgan BP.

Mult Scler. 2019 Apr;25(4):523-531. doi: 10.1177/1352458518758927. Epub 2018 Feb 9.

PMID:
29421990
30.

Multiple sclerosis: long-term outcomes in ethnic minorities. Analysis of a UK population-based registry.

Alsaeed MO, Harding KE, Williams OH, Willis MD, Hrastelj J, Tallantyre EC, Joseph FG, Wardle M, Pickersgill TP, Robertson NP.

Eur J Neurol. 2018 Apr;25(4):701-704. doi: 10.1111/ene.13571. Epub 2018 Feb 16.

PMID:
29338105
31.

Repurposing drugs to treat neurological diseases.

Massey TH, Robertson NP.

J Neurol. 2018 Feb;265(2):446-448. doi: 10.1007/s00415-018-8732-z. No abstract available.

32.

Seizures in Alzheimer's disease: is there more beneath the surface?

Edwards M, Robertson NP.

J Neurol. 2018 Jan;265(1):226-228. doi: 10.1007/s00415-017-8694-6. No abstract available.

33.

Cannabidiol as a treatment for epilepsy.

Pickrell WO, Robertson NP.

J Neurol. 2017 Dec;264(12):2506-2508. doi: 10.1007/s00415-017-8663-0. No abstract available.

34.

The economic burden of chronic neurological disease.

Wynford-Thomas R, Robertson NP.

J Neurol. 2017 Nov;264(11):2345-2347. doi: 10.1007/s00415-017-8632-7. Review. No abstract available.

35.

Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis.

Welton JL, Loveless S, Stone T, von Ruhland C, Robertson NP, Clayton A.

J Extracell Vesicles. 2017 Sep 3;6(1):1369805. doi: 10.1080/20013078.2017.1369805. eCollection 2017.

36.

Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment.

McLauchlan D, Malik GA, Robertson NP.

J Neurol. 2017 Oct;264(10):2184-2186. doi: 10.1007/s00415-017-8608-7. Review. No abstract available.

37.

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis.

Loveless S, Neal JW, Howell OW, Harding KE, Sarkies P, Evans R, Bevan RJ, Hakobyan S, Harris CL, Robertson NP, Morgan BP.

Brain Pathol. 2018 Jul;28(4):507-520. doi: 10.1111/bpa.12546. Epub 2017 Jul 30.

PMID:
28707765
38.

The role of TSPO PET in assessing neuroinflammation.

Crawshaw AA, Robertson NP.

J Neurol. 2017 Aug;264(8):1825-1827. doi: 10.1007/s00415-017-8565-1. No abstract available.

39.

Why antisense could make sense for neurodegeneration.

Massey TH, Robertson NP.

J Neurol. 2017 Jul;264(7):1542-1544. doi: 10.1007/s00415-017-8515-y. No abstract available.

40.

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis.

Willis MD, Robertson NP.

J Neurol. 2017 Jun;264(6):1298-1300. doi: 10.1007/s00415-017-8508-x. Review. No abstract available.

41.

Creutzfeldt-Jacob disease: new directions in diagnosis and therapeutics.

Al-Ansari A, Robertson NP.

J Neurol. 2017 May;264(5):1029-1031. doi: 10.1007/s00415-017-8473-4. Review. No abstract available.

42.

B cell treatments for multiple sclerosis.

McLauchlan D, Robertson NP.

J Neurol. 2017 Apr;264(4):814-816. doi: 10.1007/s00415-017-8442-y. No abstract available.

43.

Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms.

Peall KJ, Robertson NP.

J Neurol. 2017 Mar;264(3):616-618. doi: 10.1007/s00415-017-8411-5. No abstract available.

44.

Treatments in Alzheimer's disease.

Malik GA, Robertson NP.

J Neurol. 2017 Feb;264(2):416-418. doi: 10.1007/s00415-017-8395-1. No abstract available.

45.

An update on treatments in myasthenia gravis.

Jones LA, Robertson NP.

J Neurol. 2017 Jan;264(1):205-207. doi: 10.1007/s00415-016-8359-x. No abstract available.

46.

What can rare variant genetics tell us about cognition and intellectual difficulties?

Thomas RH, Robertson NP.

J Neurol. 2016 Dec;263(12):2565-2566. No abstract available.

47.

The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences.

Davies F, Wood F, Brain KE, Edwards M, Jones R, Wallbank R, Robertson NP, Edwards A.

Int J MS Care. 2016 Sep-Oct;18(5):257-264.

48.

Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies.

Clement M, Pearson JA, Gras S, van den Berg HA, Lissina A, Llewellyn-Lacey S, Willis MD, Dockree T, McLaren JE, Ekeruche-Makinde J, Gostick E, Robertson NP, Rossjohn J, Burrows SR, Price DA, Wong FS, Peakman M, Skowera A, Wooldridge L.

Sci Rep. 2016 Oct 17;6:35332. doi: 10.1038/srep35332.

49.

Ice bucket challenge bears fruit for amyotrophic lateral sclerosis.

Hrastelj J, Robertson NP.

J Neurol. 2016 Nov;263(11):2355-2357. Review. No abstract available.

50.

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.

Willis MD, Pickersgill TP, Robertson NP, Lee RWJ, Dick AD, CarreƱo E.

Int Ophthalmol. 2017 Oct;37(5):1229-1233. doi: 10.1007/s10792-016-0370-9. Epub 2016 Oct 11.

PMID:
27730316

Supplemental Content

Loading ...
Support Center